# Management of Poor Treatment Adherence in Teenage-Onset Bipolar I Disorder Using Long-Acting Injectable Second-Generation Antipsychotics: A Case Report

**Authors:** Swetha Raghavendra Prasad, Natarajan S

PMC · DOI: 10.7759/cureus.104186 · 2026-02-24

## TL;DR

This case report shows how long-acting injectable antipsychotics helped a young man with bipolar disorder maintain treatment and avoid relapse.

## Contribution

Demonstrates the effectiveness of long-acting injectables in managing non-adherence in bipolar I disorder.

## Key findings

- The patient achieved two years of stability after starting long-acting injectable paliperidone.
- Injectables improved treatment continuity and reduced relapse risk in this non-adherent patient.
- The case supports using injectables for bipolar I patients with a history of poor adherence.

## Abstract

Bipolar disorder is a chronic episodic illness in which poor treatment adherence is a major contributor to relapse, repeated hospitalization, and functional decline. We report the case of a 22-year-old self-employed man, diagnosed with bipolar I disorder at 16 years of age, who presented with irritability, aggressive behavior, reduced need for sleep, and increased goal-directed activity. He had experienced multiple manic and depressive episodes over a six-year period, largely related to repeated discontinuation of oral psychotropic medications following symptomatic improvement, and had a positive family history of mood disorder. During the current episode, clinical stabilization was achieved with electroconvulsive therapy and oral pharmacotherapy, after which a long-acting injectable second-generation antipsychotic paliperidone was initiated at discharge, and a two-year follow-up was done with clinical visits till date to address persistent non-adherence. This case highlights the potential role of long-acting injectable antipsychotics in improving treatment continuity and reducing relapse risk in selected patients with bipolar I disorder and a history of poor adherence.

## Linked entities

- **Chemicals:** paliperidone (PubChem CID 115237)
- **Diseases:** bipolar I disorder (MONDO:0001866), mood disorder (MONDO:0005371)

## Full-text entities

- **Diseases:** aggressive behavior (MESH:D010554), Bipolar I Disorder (MESH:D001714), irritability (MESH:D001523), mood disorder (MESH:D019964), depressive (MESH:D003866)
- **Chemicals:** psychotropic medications (-), paliperidone (MESH:D000068882)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC13019799